Inhibitors of KIF18A and uses thereof

A compound of Formula (Ib), or a pharmaceutically acceptable salt thereof:

• wherein,
• ring A is 4- to 6-membered heterocycloalkyl, which is optionally substituted with one or more Ra;
• L1 is C1-C6alkylene, C1-C6heteroalkylene, -heterocycloalkyl-C1-C6alkylene-, -heterocycloalkyl-C1-C6heteroalkylene-, -cycloalkyl-C1-C6alkylene-, -cycloalkyl-C1-C6heteroalkylene, —C1-C6alkylene-heterocycloalkyl-, —C1-C6heteroalkylene-heterocycloalkyl-, —C1-C6alkylene-cycloalkyl-, —C1-C6heteroalkylene-cycloalkyl-, —C1-C6heteroalkylene-cycloalkyl-C1-C6heteroalkylene, —C1-C6alkylene-cycloalkyl-C1-C6alkylene, C1-C6heteroalkylene-cycloalkyl-C1-C6alkylene, C1-C6alkylene-cycloalkyl-C1-C6heteroalkylene, —C1-C6heteroalkylene-heterocycloalkyl-C1-C6heteroalkylene, —C1-C6heteroalkylene-heterocycloalkyl-C1-C6alkylene, —C1-C6alkylene-heterocycloalkyl-C1-C6heteroalkylene, or —C1-C6alkylene-heterocycloalkyl-C1-C6alkylene, wherein each of the cycloalkyl, heterocycloalkyl, alkylene and heteroalkylene is optionally substituted with one or more Rc;
• L2 is a bond;
• X2 is N or CR2;
• X4 is N or CR4;
• Y1 is N or CH;
• Y2 is N or CH;
• Rb1 is hydrogen, C1-C6alkyl or C1-C6haloalkyl;
• Rb2 is hydrogen, C1-C6alkyl or C1-C6haloalkyl;
• R2 is hydrogen, halogen, or C1-C3alkyl;
• R4 is hydrogen or C1-C3alkyl;
• R3 is —Z—R5, and Z—R5 is selected from the group consisting of:
• —NHSO2CH2CH2OH, —NHSO2CH2CH3, —NHSO2CH3, —NHC(CH3)2CH2OH, and
• each of Ra is independently selected from halogen, —CN, —NO2, C1-C6alkyl, C1-C6haloalkyl, and C3-C6 cycloalkyl;
• each Rc is independently selected from halogen, oxo, —OH, —OR7, C1-C6haloalkyl, C1-C6alkyl, and cycloalkyl, wherein the alkyl or cycloalkyl is optionally substituted with one or more R;
• R7 is C1-C3alkyl;
• and
• each R is halogen, —CN, —OH, oxo, —SF5, —SH, —NH2, —NHC1-C3alkyl, —N(C1-C3alkyl)2, C1-C3alkyl, C1-C3alkoxy, C1-C3haloalkyl, C1-C3haloalkoxy, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl.